Prospera™ for Kidney Transplant Assessment

Prospera is a screening test designed to monitor and evaluate the risk of organ rejection post-transplant surgery. It utilizes only blood samples from organ recipients, which are then analyzed using specialized technology from the United States. This innovative testing method assesses the extent of damage to the transplanted organ, determining whether it falls within the criteria warranting monitoring for potential rejection. The need for unnecessary biopsy samples or additional medical procedures is thereby eliminated.

Prospera’s technology
Prospera employs advanced technology for screening, utilizing Next-Generation Sequencing (NGS) in combination with genetic material analysis. This technology enables the identification of differences between the genetic material of the transplanted organ and that of the organ recipient. The focus is on assessing the level of damage specific to the transplanted organ.

In cases of organ damage or rejection, the affected organ releases genetic material into the recipient’s bloodstream. Propera is capable of detecting changes in the quantity of genetic material from the donated organ. If the measured amount increases to a level requiring monitoring, it may indicate a potential risk of eventual organ loss.

Benefits of Prospera testing. Prospera testing offers several benefits:
1. Improved Detection: Prospera enhances the ability to identify organ rejection, even in cases where current medical methods may not detect it. If rejection is identified, it may often be delayed or in an advanced state of organ loss.
2. Early Detection: Early identification of transplant rejection is crucial. It enables doctors to develop effective treatment plans promptly, providing the best possible protection for donated organs.